Nektar Therapeutics
Market Cap
US$3.1b
Last Updated
2019/10/17 23:36 UTC
Data Sources
Company Financials +
Executive Summary
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.
Snowflake
Fundamentals
Excellent balance sheet and fair value.
Similar Companies
Share Price & News
How has Nektar Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
10.2%
NKTR
2.8%
US Pharmaceuticals
1.8%
US Market
1 Year Return
-64.1%
NKTR
-6.5%
US Pharmaceuticals
7.3%
US Market
Return vs Industry: NKTR underperformed the US Pharmaceuticals industry which returned -6.5% over the past year.
Return vs Market: NKTR underperformed the US Market which returned 7.3% over the past year.
Shareholder returns
| NKTR | Industry | Market | |
|---|---|---|---|
| 7 Day | 10.2% | 2.8% | 1.8% |
| 30 Day | -14.2% | 1.6% | -0.7% |
| 90 Day | -44.4% | 0.01% | 0.06% |
| 1 Year | -64.1%-64.1% | -4.3%-6.5% | 9.7%7.3% |
| 3 Year | 29.2%29.2% | 19.4%11.0% | 46.3%36.9% |
| 5 Year | 34.1%34.1% | 25.5%12.3% | 64.5%46.5% |
Price Volatility Vs. Market
How volatile is Nektar Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Nektar Therapeutics (NASDAQ:NKTR) Has Debt But No Earnings; Should You Worry?1 month ago | Simply Wall St
Those Who Purchased Nektar Therapeutics (NASDAQ:NKTR) Shares A Year Ago Have A 68% Loss To Show For It1 month ago | Simply Wall St
Have Insiders Sold Nektar Therapeutics (NASDAQ:NKTR) Shares Recently?Valuation
Is Nektar Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: NKTR ($17.77) is trading below our estimate of fair value ($101.53)
Significantly Undervalued: NKTR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NKTR is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: NKTR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate NKTR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NKTR is good value based on its PB Ratio (2x) compared to the US Pharmaceuticals industry average (2.9x).
Next Steps
Future Growth
How is Nektar Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
32.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NKTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NKTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NKTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NKTR's revenue (47.4% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: NKTR's revenue (47.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: NKTR is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Nektar Therapeutics performed over the past 5 years?
41.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: NKTR is unprofitable, but has reduced losses over the past 5 years at a rate of 41.1% per year.
Accelerating Growth: Unable to compare NKTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).
Return on Equity
High ROE: NKTR has a negative Return on Equity (-27.15%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: NKTR is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: NKTR is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Nektar Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: NKTR's short term assets ($1.6B) exceeds its short term liabilities ($113.4M)
Long Term Liabilities: NKTR's short term assets (1.6B) exceeds its long term liabilities (429.1M)
Debt to Equity History and Analysis
Debt Level: NKTR's debt to equity ratio (15.9%) is considered satisfactory
Reducing Debt: NKTR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: NKTR has a low level of unsold assets or inventory.
Debt Coverage by Assets: NKTR's debt is covered by short term assets (assets are 6.443420x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NKTR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NKTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Nektar Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate NKTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NKTR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if NKTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NKTR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NKTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Nektar Therapeutics's salary, the management and board of directors tenure and is there insider trading?
2.8yrs
Average management tenure
CEO
Howard Robin (66yo)
12.8yrs
Tenure
US$13,330,667
Compensation
Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera ...
CEO Compensation Analysis
Compensation vs. Market: Howard's total compensation ($USD13.33M) is about average for companies of similar size in the US market ($USD5.11M).
Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.8yrs
Average Tenure
56.5yo
Average Age
Experienced Management: NKTR's management team is considered experienced (2.8 years average tenure).
Board Age and Tenure
9.7yrs
Average Tenure
65yo
Average Age
Experienced Board: NKTR's board of directors are considered experienced (9.7 years average tenure).
Insider Trading
Insider Buying: NKTR insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,250 |
| Max Price | US$20.24 |
| Entity | Individual |
| Role | Chief Scientific Officer Chief Scientific Fellow |
| Shares | 15,000 |
| Max Price | US$17.28 |
| Entity | Individual |
| Role | Chief Accounting Officer Senior VP of Finance & Chief Accounting Officer |
| Shares | 1,809 |
| Max Price | US$18.15 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 12,551 |
| Max Price | US$18.15 |
| Entity | Individual |
| Shares | 3,819 |
| Max Price | US$18.15 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & COO |
| Shares | 5,063 |
| Max Price | US$18.15 |
| Entity | Individual |
| Role | Chief Scientific Officer Chief Scientific Fellow |
| Shares | 3,245 |
| Max Price | US$18.15 |
| Entity | Individual |
| Role | Chief Accounting Officer Senior VP of Finance & Chief Accounting Officer |
| Shares | 1,928 |
| Max Price | US$31.37 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 13,383 |
| Max Price | US$31.37 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & COO |
| Shares | 3,767 |
| Max Price | US$31.37 |
| Entity | Individual |
| Shares | 2,449 |
| Max Price | US$31.37 |
| Entity | Individual |
| Role | Chief Scientific Officer Chief Scientific Fellow |
| Shares | 3,461 |
| Max Price | US$31.37 |
| Entity | Individual |
| Role | Chief Accounting Officer Senior VP of Finance & Chief Accounting Officer |
| Shares | 1,808 |
| Max Price | US$42.39 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 8,882 |
| Max Price | US$42.39 |
| Entity | Individual |
| Shares | 3,822 |
| Max Price | US$42.39 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & COO |
| Shares | 3,592 |
| Max Price | US$42.39 |
| Entity | Individual |
| Shares | 2,386 |
| Max Price | US$42.39 |
| Entity | Individual |
| Role | Chief Scientific Officer Chief Scientific Fellow |
| Shares | 3,310 |
| Max Price | US$42.39 |
| Entity | Individual |
| Role | Chief Accounting Officer Senior VP of Finance & Chief Accounting Officer |
| Shares | 4,016 |
| Max Price | US$38.25 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 15,326 |
| Max Price | US$38.25 |
| Entity | Individual |
| Shares | 5,982 |
| Max Price | US$38.25 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & COO |
| Shares | 6,515 |
| Max Price | US$38.25 |
| Entity | Individual |
| Shares | 4,694 |
| Max Price | US$38.25 |
| Entity | Individual |
| Role | Chief Scientific Officer Chief Scientific Fellow |
| Shares | 4,524 |
| Max Price | US$38.25 |
Ownership Breakdown
Management Team
Howard Robin (66yo)
CEO, President & Director
- Tenure: 12.8yrs
- Compensation: US$13.33m
Gilbert Labrucherie (47yo)
CFO & COO
- Tenure: 3.3yrs
- Compensation: US$5.73m
Brian Kotzin (70yo)
Senior VP of Clinical Development & Head of Immunology Program
- Tenure: 2.4yrs
Steve Doberstein (60yo)
Chief Scientific Fellow
- Tenure: 0.8yrs
- Compensation: US$4.81m
Mary Tagliaferri (53yo)
Chief Medical Officer
- Tenure: 1.9yrs
Jillian Thomsen (53yo)
Senior VP of Finance & Chief Accounting Officer
- Tenure: 11.5yrs
- Compensation: US$6.23m
Dorian Hirth
Senior Vice President of Human Resources and Facilities Operations
- Tenure: 0yrs
Jonathan Zalevsky
Chief Research & Development Officer
- Tenure: 0yrs
Jennifer Ruddock
Senior Vice President of Strategy & Corporate Affairs
- Tenure: 0.8yrs
Mark Wilson
Senior VP
- Tenure: 3.3yrs
Board Members
Karin Eastham (70yo)
Independent Director
- Tenure: 1.1yrs
- Compensation: US$1.14m
Rob Chess (62yo)
Independent Chairman of the Board
- Tenure: 20.5yrs
- Compensation: US$741.55k
R. Greer (61yo)
Independent Director
- Tenure: 9.7yrs
- Compensation: US$732.55k
Roy Whitfield (65yo)
Lead Independent Director
- Tenure: 0.8yrs
- Compensation: US$708.30k
Howard Robin (66yo)
CEO, President & Director
- Tenure: 12.8yrs
- Compensation: US$13.33m
Lutz Lingnau (76yo)
Independent Director
- Tenure: 12.2yrs
- Compensation: US$715.30k
Jeff Ajer (57yo)
Independent Director
- Tenure: 2.1yrs
- Compensation: US$709.05k
Company Information
Nektar Therapeutics's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nektar Therapeutics
- Ticker: NKTR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.115b
- Shares outstanding: 175.27m
- Website: https://www.nektar.com
Number of Employees
Location
- Nektar Therapeutics
- 455 Mission Bay Boulevard South
- San Francisco
- California
- 94158
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NKTR | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 1994 |
| ITH | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 1994 |
| 0UNL | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 1994 |
| NKTR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 1994 |
Biography
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which i ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 23:36 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.